price aug usd
strong set tone
came ahead expect import margin leverag show-
ing result allay two key investor concern head print
achiev full year revenu guidanc given multitud near-term
headwind meaning back half acceler howev post full-
year outlook cc appear achiev think actual conserv-
ativ given manag refrain up outlook despit
cal robot diabet pump tavr low risk tyrx micra av linq among
notabl meaning easier comp back half dcb lvad
headwind start anniversari
flipsid us diabet perform remain challeng
competit pressur particularli continu share loss
ahead multipl upcom new product introduct notabl
compani still expect launch launch critic
stem bleed return us diabet busi growth though
segment perform promis remain sluggish evidenc
segment guidanc cut obviou advantag
like blue tooth connect reduc set chang everi three
day week unabl answer form factor question
caus share loss posit note intern diabet
franchis continu post strong growth could strengthen
throughout year germani franc provid reimburs
question around mdt abil achiev target oper margin
improv year given inconsist perform recent histori
concern front likewis allay solid execut healthi
profit gain ebit margin increas cc full-
year guidanc firmli intact line model oper profit
key metric mdt senior manag discretionari compens
structur clearli appear yield better execut soon
declar victori clearli move right direct give increas-
ing confid investor margin leverag come
deutsch bank seek busi compani cover research report thu investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis disclosur analyst certif locat
distribut gmt
guidanc estim move higher see potenti earn upsid
tax line bottom line sale guidanc unchang
up forecast ep rang dime driven princip
upsid last month refinanc lower effect tax rate
lower opex non-opex expens alreadi
factor lower interest expens post-refi though appear
suffici contempl consensu ahead result ep
estim move modest regard tax rate continu
believ could potenti meaning ep upsid perhap tune
compani continu formul tax mitig strate-
gie light pend corpor tax reform final
come month ahead manag refrain updat out-
look expens line
rais pt remain buy remain construct share
basi acceler organ revenu growth continu oper leverag
capit deploy best-in-class convers firm commit-
ment return free cash sharehold employ
target valuat multipl versu previous think warrant
guidanc meaning de-risk investor enthusiasm grow
regard major upcom product launch particularli highli anticip
hugo surgic robot platform remain track commerci introduct
ye appli multipl ftm earn forecast month henc
arriv new pt coupl dividend yield pt impli
double-digit total sharehold return next month thu justifi
buy risk invest thesi includ share loss within key product cate-
gori clinical/regulatory/commerci setback key pipelin program fail-
ure consist deliv margin target
investor event septemb
sept mitg analyst meet hartford ct unveil hugo surgic robot
expect detail around capabl target procedur sale model
specif ou us launch time
figur summari revenu guidanc updat db estim
uct categori though result came meaning better expect
guidanc call flat sale
revenu declin driven lsd declin icd includ crt us
msd consist preview continu challeng
unfavor product cycl continu uptak emblem s-icd replac
cycl owe longer batteri life mdt latest crt-d dynam
expect persist time
pacemak strong us ww hsd driven continu
uptak micra leadless transcathet pacemak thank
two-third share us single-chamb segment unit basi
dollar market importantli current micra vr iter limit
singl chamber categori util patient av block concomi-
tant af thu limit address market bradi patient
howev next gener micra av also util patient av
block normal atrial function thu tripl address market
estim overal pacemak market longer term compani
expect leadless pacer abl address close market
time-frame long-term outlook differenti technolog platform
remain posit term posit continu above-market pace-
maker growth next sever year particularli light strong adopt
micra vr
reveal linq increas ldd us hsd global upcom launch
linq w/bluetooth connect addit diagnost capabl later
year help sustain momentum
af growth came think us lsd ww hsd though
upcom launch new cathet address paroxysm persist-
ent af segment help reinvigor growth still highli underpenetrat-
tyrx growth healthi ww continu acceler post
robust wrap-it result march show reduct
implant penalti vi -- vi procedur time advers event
consist strong acceler weve seen recent month us
continu think tyrx could ultim becom substanti revenu con-
tributor mdt franchis next year anti-infec-
tion envelop use non-mdt implant expect collater
uplift compani devic continu work medic socie-
tie inclus updat guidelin implant longer term
compani also see util busi
lvad weak ww us owe
cyclic structur headwind expect sale remain depress
continu captur share follow approv destin therapi
revenu increas reflect strength corevalv mid-teen ww par-
tialli off-set continu de headwind regard tavr manag com-
mentari around expect impact updat ncd quit bullish includ
expect new us center come board near-term note
compani activ discuss half site potenti pre-
fer vendor follow last week low-risk approv market growth promis
expect dcb continu pressur low ww low
us light continu focu around safeti potenti increas late mor-
taliti said perform quarter meaning better anticipat-
ed actual see acceler post june panel agenc
re-affirmed favor risk/reward particularli high risk patient
believ acceler product specif panel provid
opportun showcas robust bodi data pact clinic differentia-
tion versu competitor devic expect dcb remain drag next cou-
ple quarter decemb jaha meta-analysi public anniversa-
aortic stent graft side healthi result driven taa high-teen
us mid-teen ww though aaa growth remain sluggish us/ww
segment sale increas result neg impact supplier
steril issu importantli fulli remedi lead
better mitg result begin evidenc updat guidanc
obvious big focu remain hugo surgic robot manage-
ment final debut street analyst meet septemb hart-
ford ct ahead detail around commerci strategi limit
today call look color next month meet
sale increas driven advanc surgic advanc energi devi-
ce grew hsd advanc stapl msd gener surgic catego-
ry declin lsd owe aforement suppli disrupt
growth reflect balanc growth across portfolio patient moni-
tore msd gi solut ldd respiratori msd renal msd
segment sale increas continu strength brain therapi partial
off-set pain therapi one area weak mdt
growth propel strength neurovascular mid-teen
neurosurgeri ldd
within neurovascular compani note doubl digit growth hemor-
rhagic flow divers high teen coil ldd ischem driven solitair
 stent retriev react aspir catheters/riptid aspir system stroke
therapi recent competitor launch clearli stymi momentum
neurosurgeri ldd growth result strength across capit equip
offer stealthstat o-arm placement collater benefit
interest mazor robot placement strong though
longer quantifi placement number note call
mazor stealth instal first half doubl
competitor combin
spine growth manag cite strength cervic implant
infus togeth spine-en equip consist
spine player report result note growth basi
us even stronger notabl given mani year market
under-perform seen import categori remain mar-
pain therapi sale declin owe weak howev impor-
tantli manag attribut custom destock rather implant vol-
ume compani note yr/yr growth actual posit nevertheless
given diverg result market player debat around mar-
ket growth promis continu
price current end previou trade session unless otherwis indic sourc local exchang via reuter bloomberg vendor
inform sourc deutsch bank subject compani sourc disclosur pertain recommend estim made secur primari
subject research pleas see recent publish compani report visit global disclosur look-up page websit http //research db com/research/disclosures/
companysearch asid within report import risk conflict disclosur also found investor
strongli encourag review inform invest
import disclosur requir regul
disclosur mark asterisk may also requir least one jurisdict addit unit state see
import disclosur requir non-u regul explanatori note
within past year deutsch bank and/or affili manag co-manag public privat offer
compani receiv fee
deutsch bank and/or affili receiv compens compani provis invest
bank financi advisori servic within past year
deutsch bank and/or affili expect receiv intend seek compens invest bank
servic compani next three month
deutsch bank and/or affili receiv non-invest bank relat compens compani
within past year
compani client deutsch bank secur inc within past year time receiv
import disclosur requir non-u regul
disclosur mark asterisk may also requir least one jurisdict addit unit state see
import disclosur requir non-u regul explanatori note
within past year deutsch bank and/or affili manag co-manag public privat offer
compani receiv fee
deutsch bank and/or affili receiv compens compani provis invest
bank financi advisori servic within past year
disclosur pertain recommend estim made secur primari subject
